• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

Recent Advances in the Study of 4-Bromo-3-(trifluoromethyl)-1-trityl-1H-pyrazole (CAS: 474706-50-8)

4-Bromo-3-(trifluoromethyl)-1-trityl-1H-pyrazole (CAS: 474706-50-8) is a specialized pyrazole derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry. This compound, characterized by its bromo and trifluoromethyl substituents, serves as a crucial intermediate in the synthesis of various biologically active molecules. Recent studies have explored its potential applications in drug discovery, particularly in the development of kinase inhibitors and anti-inflammatory agents. The unique structural features of this compound, including the trityl-protecting group, make it a versatile building block for the construction of complex heterocyclic systems.

In a recent publication in the Journal of Medicinal Chemistry, researchers investigated the role of 4-Bromo-3-(trifluoromethyl)-1-trityl-1H-pyrazole in the synthesis of novel Janus kinase (JAK) inhibitors. The study highlighted the compound's ability to undergo selective cross-coupling reactions, enabling the efficient introduction of diverse pharmacophores. The resulting JAK inhibitors exhibited potent activity against JAK2 and JAK3 isoforms, with IC50 values in the low nanomolar range. These findings underscore the compound's utility in the design of targeted therapies for autoimmune diseases and hematologic malignancies.

Another study, published in ACS Chemical Biology, focused on the use of 4-Bromo-3-(trifluoromethyl)-1-trityl-1H-pyrazole as a precursor for the development of covalent inhibitors. The researchers employed a structure-based drug design approach to modify the pyrazole core, resulting in compounds that selectively target cysteine residues in the active sites of disease-relevant proteins. The study demonstrated that the trifluoromethyl group enhances the electrophilicity of the pyrazole ring, facilitating the formation of stable covalent adducts with target proteins. This strategy holds promise for the development of irreversible inhibitors with improved potency and selectivity.

In addition to its applications in drug discovery, 4-Bromo-3-(trifluoromethyl)-1-trityl-1H-pyrazole has also been explored in materials science. A recent report in Advanced Materials described its use as a key intermediate in the synthesis of organic semiconductors. The compound's ability to undergo palladium-catalyzed coupling reactions was leveraged to construct extended π-conjugated systems with tunable electronic properties. These materials exhibited high charge carrier mobility, making them suitable for use in organic field-effect transistors (OFETs) and photovoltaic devices.

Despite these advancements, challenges remain in the large-scale synthesis and purification of 4-Bromo-3-(trifluoromethyl)-1-trityl-1H-pyrazole. Recent efforts have focused on optimizing reaction conditions to improve yield and reduce the formation of byproducts. For instance, a study in Organic Process Research & Development reported the successful use of continuous flow chemistry to achieve gram-scale production of the compound with high purity (>98%). This approach not only enhances efficiency but also minimizes the environmental impact associated with traditional batch processes.

Looking ahead, the versatility of 4-Bromo-3-(trifluoromethyl)-1-trityl-1H-pyrazole is expected to drive further innovation in both pharmaceutical and materials science applications. Ongoing research aims to expand the scope of its reactivity, enabling the synthesis of even more complex and functionalized derivatives. As our understanding of its chemical behavior deepens, this compound is likely to play an increasingly important role in the development of next-generation therapeutics and advanced materials.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)